{'fraction_non_alphanumeric': 0.01636904761904762, 'fraction_numerical': 0.0, 'mean_word_length': 5.533980582524272, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interview with Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry.

The global Pharma industry is facing numerous challenges, from a slowdown in successful innovations and increasing R&D costs, to threats to revenue of imminent patent expirations and the impact of generic products. These and other factors are resulting in companies adopting new strategies to reassess and diversify their business and R&D models. Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry, spoke to Future Medicinal Chemistry about the key issues affecting the industry and the approaches for overcoming them.